|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
LU86084A1
(fr)
|
1985-09-20 |
1987-04-02 |
Faco Sa |
Apparei de massage electrique
|
|
US5102417A
(en)
|
1985-11-07 |
1992-04-07 |
Expandable Grafts Partnership |
Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
|
|
US4800882A
(en)
|
1987-03-13 |
1989-01-31 |
Cook Incorporated |
Endovascular stent and delivery system
|
|
US4886062A
(en)
|
1987-10-19 |
1989-12-12 |
Medtronic, Inc. |
Intravascular radially expandable stent and method of implant
|
|
WO1990013332A1
(en)
|
1989-05-11 |
1990-11-15 |
Cedars-Sinai Medical Center |
Stent with sustained drug delivery
|
|
WO1991012779A1
(en)
|
1990-02-28 |
1991-09-05 |
Medtronic, Inc. |
Intralumenal drug eluting prosthesis
|
|
US5419760A
(en)
|
1993-01-08 |
1995-05-30 |
Pdt Systems, Inc. |
Medicament dispensing stent for prevention of restenosis of a blood vessel
|
|
US5429634A
(en)
|
1993-09-09 |
1995-07-04 |
Pdt Systems |
Biogenic implant for drug delivery and method
|
|
US6774278B1
(en)
|
1995-06-07 |
2004-08-10 |
Cook Incorporated |
Coated implantable medical device
|
|
DE19539091A1
(de)
|
1995-10-20 |
1997-04-24 |
Thomae Gmbh Dr K |
5-gliedrige Heterocyclen, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zur ihrer Herstellung
|
|
JPH11513382A
(ja)
|
1995-10-20 |
1999-11-16 |
ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
|
|
US5833651A
(en)
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
|
GT200100147A
(es)
|
2000-07-31 |
2002-06-25 |
|
Derivados de imidazol
|
|
US6756385B2
(en)
|
2000-07-31 |
2004-06-29 |
Pfizer Inc. |
Imidazole derivatives
|
|
KR20030030029A
(ko)
|
2000-09-22 |
2003-04-16 |
니혼노야쿠가부시키가이샤 |
Ｎ-(4-피라졸릴)아미드 유도체 및 농원예용 약제 그리고그 사용방법
|
|
US7589199B2
(en)
*
|
2002-06-12 |
2009-09-15 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US20050256130A1
(en)
*
|
2002-06-12 |
2005-11-17 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US7842693B2
(en)
|
2002-06-12 |
2010-11-30 |
Chemocentryx, Inc. |
Substituted piperazines
|
|
US6770729B2
(en)
|
2002-09-30 |
2004-08-03 |
Medtronic Minimed, Inc. |
Polymer compositions containing bioactive agents and methods for their use
|
|
BRPI0409949A
(pt)
|
2003-05-01 |
2006-04-25 |
Bristol Myers Squibb Co |
compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
|
|
EP1883646A1
(en)
|
2005-05-19 |
2008-02-06 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
|
ES2543714T3
(es)
|
2005-06-22 |
2015-08-21 |
Chemocentryx, Inc. |
Compuestos de azaindazol y métodos de uso
|
|
US7777035B2
(en)
|
2005-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
FR2887450B1
(fr)
|
2005-06-23 |
2007-08-24 |
Rhodia Chimie Sa |
Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
|
|
WO2007026834A1
(ja)
|
2005-09-01 |
2007-03-08 |
Kumiai Chemical Industry Co., Ltd. |
ピラゾール誘導体及び農園芸用除草剤
|
|
WO2007044804A2
(en)
*
|
2005-10-11 |
2007-04-19 |
Chemocentryx, Inc. |
Piperidine derivatives and methods of use
|
|
US20090252779A1
(en)
|
2006-06-22 |
2009-10-08 |
Chemocentryx, Inc. |
Azaindazole compounds and methods of use
|
|
CA2675511A1
(en)
|
2006-10-10 |
2008-04-17 |
Amgen Inc. |
N-aryl pyrazole compounds for use against diabetes
|
|
WO2008072724A1
(ja)
*
|
2006-12-14 |
2008-06-19 |
Taisho Pharmaceutical Co., Ltd. |
ピラゾール誘導体
|
|
US7786157B2
(en)
|
2007-03-16 |
2010-08-31 |
Chemocentryx, Inc. |
OXO-imidazolidines as modulators of chemokine receptors
|
|
CN101743238B
(zh)
|
2007-05-22 |
2014-04-30 |
凯莫森特里克斯股份有限公司 |
3-(咪唑基)-吡唑并[3,4-b]吡啶
|
|
NZ600758A
(en)
|
2007-06-18 |
2013-09-27 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
|
EP2170309B1
(en)
|
2007-06-22 |
2016-10-26 |
Hydra Biosciences, Inc. |
2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
|
|
AU2008321823B2
(en)
*
|
2007-11-13 |
2013-03-07 |
Taisho Pharmaceutical Co., Ltd. |
Phenylpyrazole derivatives
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
EP2297112B1
(en)
|
2008-05-06 |
2013-04-03 |
Boehringer Ingelheim International GmbH |
Pyrazole compounds as ccr1 antagonists
|
|
US20120108614A1
(en)
|
2008-05-14 |
2012-05-03 |
Chong Jayhong A |
Compounds and compositions for treating chemical warfare agent-induced injuries
|
|
PL2323663T3
(pl)
*
|
2008-09-11 |
2015-08-31 |
Chemocentryx Inc |
4-amino-3-(imidazolilo)-pirazolo[3,4,-d]pirymidyny
|
|
ES2592216T3
(es)
|
2008-09-26 |
2016-11-28 |
Dana-Farber Cancer Institute, Inc. |
Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
|
|
WO2010053861A2
(en)
|
2008-11-07 |
2010-05-14 |
H. Lundbeck A/S |
Biologically active amides
|
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
|
GB0915892D0
(en)
|
2009-09-10 |
2009-10-14 |
Smithkline Beecham Corp |
Compounds
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
EP2785375B1
(en)
|
2011-11-28 |
2020-07-22 |
Merck Patent GmbH |
Anti-pd-l1 antibodies and uses thereof
|
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
|
US9422339B2
(en)
|
2012-03-29 |
2016-08-23 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
EP2855528B1
(en)
|
2012-05-31 |
2019-06-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US20140164267A1
(en)
|
2012-12-07 |
2014-06-12 |
Optionality Holdings Inc. |
Compliance service
|
|
WO2014089495A1
(en)
|
2012-12-07 |
2014-06-12 |
Chemocentryx, Inc. |
Diazole lactams
|
|
EP2935227B1
(en)
|
2012-12-21 |
2017-09-13 |
ChemoCentryx, Inc. |
Diazole amides as ccr1 receptor antagonists
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
DK3021869T3
(da)
|
2013-07-16 |
2020-09-21 |
Hoffmann La Roche |
Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
|
|
KR102232153B1
(ko)
|
2013-08-20 |
2021-03-24 |
머크 샤프 앤드 돔 코포레이션 |
Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
|
|
EA029901B1
(ru)
|
2013-09-04 |
2018-05-31 |
Бристол-Майерс Сквибб Компани |
Соединения для применения в качестве иммуномодуляторов
|
|
KR20160075506A
(ko)
|
2013-09-06 |
2016-06-29 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절제로서 사이클릭 펩티도미메틱 화합물
|
|
CU24345B1
(es)
|
2013-09-06 |
2018-05-08 |
Aurigene Discovery Tech Ltd |
Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
|
|
DK3363790T3
(da)
|
2013-09-06 |
2020-04-27 |
Aurigene Discovery Tech Ltd |
1,2,4-oxadiazolderivater som immunmodulatorer
|
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
|
AU2015267052A1
(en)
|
2014-05-27 |
2016-12-15 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
MA40132B1
(fr)
|
2014-09-11 |
2019-04-30 |
Bristol Myers Squibb Co |
Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
|
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
SG11201706902SA
(en)
|
2015-03-10 |
2017-09-28 |
Aurigene Discovery Tech Ltd |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
|
CU20170116A7
(es)
|
2015-03-10 |
2018-06-05 |
Aurigene Discovery Tech Ltd |
Compuestos cíclicos terapéuticos como inmunomoduladores
|
|
CU24509B1
(es)
|
2015-03-10 |
2021-05-12 |
Aurigene Discovery Tech Ltd |
Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
|
|
KR20170125931A
(ko)
|
2015-03-10 |
2017-11-15 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절제로서의 3-치환된 1,3,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
BR112017019306A2
(pt)
|
2015-03-10 |
2018-05-08 |
Aurigene Discovery Technologies Limited |
compostos de 1,3,4-oxadiazol e tiadiazol como imunomoduladores
|
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
|
PL3439653T3
(pl)
|
2016-04-07 |
2021-07-05 |
Chemocentryx, Inc. |
Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
|